References and Notes
<A NAME="RG09409ST-1">1</A>
Aspirant of the Research Foundation - Flanders
(FWO-Vlaanderen).
<A NAME="RG09409ST-2A">2a</A>
O’Hagan D.
Chem. Soc. Rev.
2008,
37:
308
<A NAME="RG09409ST-2B">2b</A>
Purser S.
Moore PR.
Swallow S.
Gouverneur V.
Chem. Soc. Rev.
2008,
37:
320
<A NAME="RG09409ST-2C">2c</A>
Kirk KL.
Org. Process Res. Dev.
2008,
12:
305
<A NAME="RG09409ST-2D">2d</A>
Müller K.
Faeh C.
Diederich F.
Science
2007,
317:
1881
<A NAME="RG09409ST-2E">2e</A>
Isanbor C.
O’Hagan D.
J. Fluorine
Chem.
2006,
127:
303
<A NAME="RG09409ST-2F">2f</A>
Bégué J.-P.
Bonnet-Delpon D.
J.
Fluorine Chem.
2006,
127:
992
<A NAME="RG09409ST-2G">2g</A>
Kirk
KL.
J. Fluorine Chem.
2006,
127:
1013
<A NAME="RG09409ST-3">3</A>
De Matteis V.
van Delft FL.
Tiebes J.
Rutjes FP.
Eur. J.
Org. Chem.
2006,
1166
<A NAME="RG09409ST-4">4</A>
Verniest G.
Surmont R.
Van Hende E.
Deweweire A.
Deroose F.
Thuring JW.
De Kimpe N.
J. Org. Chem.
2008,
73:
5458
<A NAME="RG09409ST-5">5</A>
Allen JG,
Krasutsky AP,
Wallace OB,
Xu Y, and
York JS. inventors; WO 2007127693.
; Chem. Abstr. 2007, 147, 522085
<A NAME="RG09409ST-6">6</A>
Tai VW.-F.
Sperandio D.
Shelton EJ.
Litvak J.
Pararajasingham K.
Cebon B.
Lohman J.
Eksterowicz J.
Kantak S.
Sabbatini P.
Brown C.
Zeitz J.
Reed C.
Maske B.
Graupe D.
Estevez A.
Oeh J.
Wong D.
Ni Y.
Sprengeler P.
Yee R.
Magill C.
Neri A.
Cai SX.
Drewe J.
Qiu L.
Herich J.
Tseng B.
Kasibhatla S.
Spencer JR.
Bioorg.
Med. Chem. Lett.
2006,
16:
4554
<A NAME="RG09409ST-7">7</A>
Norman MH,
Pettus LH,
Wang X, and
Zhu J. inventors; US 2006058308.
; Chem. Abstr. 2006, 144, 312100
<A NAME="RG09409ST-8">8</A>
Micheli F.
Pasquarello A.
Tedesco G.
Hamprecht D.
Bonanomi G.
Checchia A.
Jaxa-Chamiec A.
Damiani F.
Davalli S.
Donati D.
Gallotti C.
Petrone M.
Rinaldi M.
Riley G.
Terreni S.
Wood M.
Bioorg. Med. Chem. Lett.
2006,
16:
3906
<A NAME="RG09409ST-9A">9a</A>
Berlin M.
Ting PC.
Vaccaro WD.
Aslanian R.
McCormick KD.
Lee JF.
Albanese MM.
Mutahi
MW.
Piwinski JJ.
Shih N.-Y.
Duguma L.
Solomon DM.
Zhou W.
Sher R.
Favreau L.
Bryant M.
Korfmacher WA.
Nardo C.
West RE.
Anthes JC.
Williams SM.
Wu R.-L.
She HS.
Rivelli MA.
Corboz MR.
Hey JA.
Bioorg.
Med. Chem. Lett.
2006,
16:
989
<A NAME="RG09409ST-9B">9b</A>
Davey D,
Lee W,
Lu S.-F,
Phillips G,
Wei GP, and
Ye B. inventors; US 2005101644.
; Chem. Abstr. 2005, 142, 463444
<A NAME="RG09409ST-9C">9c</A>
Deshpande PK,
Sindkhedkar MD,
Phansalkar MS,
Yeole RD,
Gupte SV,
Chugh Y,
Shetty N,
Bhagwat SS,
De Souza NJ, and
Patel MV. inventors;
WO 2005054234.
; Chem. Abstr. 2005, 143, 59964
<A NAME="RG09409ST-9D">9d</A>
Blizzard TA.
DiNinno F.
Morgan JD.
Wu JY.
Chen HY.
Kim S.
Chan W.
Birzin ET.
Yang YT.
Pai L.-Y.
Zhang Z.
Hayes EC.
DaSilva CA.
Tang W.
Rohrer SP.
Schaeffer JM.
Hammond ML.
Bioorg. Med.
Chem. Lett.
2004,
14:
3865
<A NAME="RG09409ST-10A">10a</A>
Fatheree P,
Gendron R,
Goldblum AA,
Long DD,
Marquess D,
Turner SD, and
Choi S.-K. inventors; US 2006135764.
; Chem. Abstr. 2006, 145, 83322
<A NAME="RG09409ST-10B">10b</A>
John V,
Moon JB,
Pulley SR,
Rich DH,
Brown DL,
Jagodzinska B, and
Jacobs JS. inventors; WO 2003043987.
; Chem. Abstr. 2003, 139, 6887
<A NAME="RG09409ST-10C">10c</A>
Stanton MG,
Munoz B,
Sloman DL,
Hubbs J, and
Hamblett C. inventors; WO 2008030391.
; Chem. Abstr. 2008, 148, 331574
<A NAME="RG09409ST-10D">10d</A>
Burger M,
Lindvall M,
Han W,
Lan J,
Nishiguchi G,
Shafer C,
Bellamacina C,
Huh K,
Atallah G,
McBride C,
Antonios-McCrea W,
Zavorotinskaya T,
Walter A, and
Garcia P. inventors; WO 2008106692.
; Chem. Abstr. 2008, 149, 332352
<A NAME="RG09409ST-11">11</A>
Zacuto MJ.
Caia D.
Tetrahedron Lett.
2005,
46:
447
<A NAME="RG09409ST-12">12</A>
Lal GS.
Pez GP.
Pesaresi RJ.
Prozonic FM.
Chem. Commun.
1999,
215
<A NAME="RG09409ST-13">13</A>
3-Benzyloxy-4,4-difluoro-1-(trifluoroacetyl)piperidine (9a)
In a 25 mL flask, 3-benzyloxy-1-(trifluoroacetyl)-4-piperidinone
(8a, 0.30 g, 1.00 mmol) was dissolved in
anhyd CH2Cl2 (10 mL). The solution was cooled
to -78 ˚C under nitrogen atmosphere and
morpholinosulfur trifluoride (Morph-DAST; 0.53 g, 3.00 mmol, 3 equiv,
0.37 mL) was added dropwise. The reaction mixture was allowed to
warm to r.t. over 1 h and was stirred for 2 h at the same temperature.
The mixture was poured in CH2Cl2 (10 mL) and
H2O (10 mL). The separated aqueous phase was extracted
twice with CH2Cl2 (10 mL), and the combined organic
phases were dried over MgSO4. After filtration, the solvent
was evaporated in vacuo, and the concentrate was purified via flash
chromatography over silica gel (hexane-EtOAc = 83:17, R
f
= 0.29)
yielding 0.24 g of piperidine 9a (0.73
mmol, 73%). Ratio of rotamers = 3:2; colorless
oil. ¹H NMR (300 MHz, CDCl3): δmajor = 1.88-2.05
(1 H, m, NCH2CH
aHb),
2.17-2.43 (1 H, m, NCH2CHa
H
b), 3.21 (1 H, br d, J = 14.9 Hz,
NCH
aHbCH), 3.37
(1 H, ddd, J = 14.5, 11.4,
3.2 Hz, NCH
aHbCH2),
3.55-3.73 (1 H, m, OCH), 3.80-3.93 (1 H, m, NCHa
H
bCH2), 4.44-4.53
(1 H, m, NCHa
H
bCH),
4.63 (1 H, d, J = 11.8
Hz, CH
aHbPh), 4.71
(1 H, d, J = 11.8
Hz, CHa
H
bPh), 7.21-7.44
(5 H, m, 5 × CHar); δminor = 1.88-2.05
(1 H, m, NCH2CH
aHb),
2.17-2.43 (1 H, m, NCH2CHa
H
b), 3.27 (1 H, ddd, J = 14.0,
10.5, 3.4 Hz, NCH
aHbCH2),
3.48 (1 H, br d, J = 14.3
Hz, NCH
aHbCH), 3.55-3.73
(1 H, m, OCH), 3.80-3.93 (1 H, m, NCHa
H
bCH), 4.10-4.21
(1 H, m, NCHa
H
bCH2),
4.64 (1 H, d, J = 11.6
Hz, CH
aHbPh), 4.74
(1 H, d, J = 11.6
Hz, CHa
H
bPh), 7.21-7.44 (5
H, m, 5 × CHar). ¹9F
NMR (282 MHz, CDCl3): δ = -67.8 and -68.8
(3 F, s, CF3), -107.4 (1 F, dd, J = 247.6,
24.3 Hz, CF
aFb,rotamer1), -107.6
(1 F, br d, J = 247.6
Hz, CF
aFb,rotamer2), -108.5
(1 F, br d, J = 247.6
Hz, CFa
F
b,rotamer1), -109.2
(1 F, br d, J = 247.6
Hz, CFa
F
b,rotamer2). ¹³C
NMR (75 MHz, CDCl3): δ = 30.3 and 31.1
(t, J = 22.8
Hz), 40.1 and 42.3, 44.1 and 47.0, 72.5 and 73.4, 73.1 and 73.5
(t, J = 20.5
Hz), 116.5 (q, J = 288.2
Hz), 120.0 (t, J = 246.9
Hz) and 120.6 (dd, J = 250.4,
244.6 Hz), 128.0, 128.1, 128.2, 128.4, 128.7, 136.9 and 137.1, 156.4
and 156.5 (q, J = 36.2
Hz). IR (NaCl): ν = 1699, 1203,
1116 cm-¹. GC-MS (EI): m/z (%) = 323
(22) [M+], 107 (71) [C7H9O+],
91 (100) [C7H7
+].
Anal. Calcd: C, 52.02; H, 4.37; N, 4.33. Found: C, 51.76; H, 4.11; N,
4.01.
<A NAME="RG09409ST-14">14</A>
3-Benzyloxy-4,4-difluoropiperidine (10)
In a 25 mL flask, 3-benzyloxy-4,4-difluoro-1-(trifluoro- acetyl)piperidine
(9a, 0.50 g, 1.55 mmol) was dissolved in MeOH
(6 mL). A solution of K2CO3 (0.64 g, 4.64
mmol, 3 equiv) in H2O (3 mL) was added, and the mixture
was stirred for 12 h at r.t. After completion of the reaction, the
solvent was evaporated in vacuo, and the residue was dissolved in CH2Cl2 (20
mL) and H2O (20 mL). The separated aqueous phase was
extracted twice with CH2Cl2 (20 mL) and the combined
organic phases dried over MgSO4. After filtration, the
solvent was evaporated in vacuo, yielding 0.35 g of piperidine 10 (1.55 mmol, 100%, purity >92%).
For analytical purposes a 50 mg sample of the compound was subjected
to an acid-base extraction (30% yield), excluding the
necessity of flash chromatography to yield pure compound 10 as a yellow oil. ¹H
NMR (300 MHz, CDCl3): δ = 1.48-1.72
(1 H, br s, NH), 1.87 (1 H, dddt, J = 24.7,
13.0, 4.0, 1.3 Hz, CH
aHb),
2.12 (1 H, dddd, J = 35.4,
13.0, 10.2, 5.0 Hz, CHa
H
b),
2.73-2.91 (2 H, m, NCH
2CH2),
2.91-3.10 (2 H, m, NCH
2CH),
3.45-3.54 (1 H, m, OCH), 4.63 (1 H, d, J = 11.8
Hz, OCH
aHb), 4.80
(1 H, d, J = 11.8
Hz, OCHa
H
b), 7.27-7.38
(5 H, m, 5 × CHar). ¹9F
NMR (282 MHz, CDCl3): δ = -104.9
(1 F, br s),-105.7 (1 F, br s). ¹³C
NMR (75 MHz, CDCl3): δ = 32.5 (t, J = 20.8 Hz),
42.8 (t, J = 4.0
Hz), 48.4 (t, J = 2.3
Hz), 72.8, 74.7 (t, J = 24.8
Hz), 121.6 (t, J = 247.5 Hz),
127.8, 127.9, 128.4, 137.7. IR (ATR): ν = 3324,
3032, 2930, 1454, 1351, 1200, 1111, 967, 737, 698 cm-¹.
MS (ES+): m/z (%) = 228
(100) [M + H+]. Anal.
Calcd: C, 63.42; H, 6.65; N, 6.13. Found: C, 63.08; H, 6.01; N,
5.95.
<A NAME="RG09409ST-15">15</A>
4,4-Difluoro-3-hydroxy-1-(trifluoroacetyl)piperidine
(11)
In a dry pressure vessel,
3-benzyloxy-4,4-difluoro-1-(trifluoroacetyl)piperidine (9a, 1.10 g, 3.40 mmol) was dissolved in
EtOAc (10 mL). After adding 10% Pd/C (0.22 g)
at 0 ˚C, the mixture was stirred during 15 h at
r.t. under hydrogen pressure of 4.75 bar. The mixture was filtered
over Celite®, and the filtrate was evaporated
in vacuo to yield 0.75 g of pure piperidine 11 (3.20
mmol, 94%). Ratio of rotamers = 53:47; yellow
oil. ¹H NMR (300 MHz, CDCl3): δmajor = 1.93-2.11
(1 H, m, NCH2CH
aHb),
2.18-2.48 (1 H, m, NCH2CHa
H
b), 2.60-3.10 (1
H, br s, OH), 3.47 (1 H, d × m, J = 13.8 Hz,
NCH
aHbCH), 3.46-3.54
(1 H, m, NCH
aHbCH2),
3.81-3.95 (1 H, m, NCHa
H
bCH2),
3.97-4.05 (1 H, m, OCH), 4.28 (1 H, d × m, J = 13.8 Hz,
NCHa
H
bCH); δminor = 1.93-2.11
(1 H, m, NCH2CH
aHb),
2.18-2.48 (1 H, m, NCH2CHa
H
b), 2.60-3.10 (1
H, br s, OH), 3.41 (1 H, ddd, J = 13.8,
10.0, 3.7 Hz, NCH
aHbCH2),
3.65 (1 H, d, J =
13.8
Hz, NCH
aHbCH),
3.81-3.95 (2 H, m, OCH and NCHa
H
bCH),
4.14 (1 H, dt, J = 13.8,
4.8 Hz, NCHa
H
bCH2). ¹9F
NMR (282 MHz, CDCl3): δ = -67.8
and -68.9 (3 F, s, CF3), -110.1 (1
F, dd, J = 246.0,
21.1 Hz, CF
aFb,rotamer1),
-110.4
(1 F, dd, J = 246.0,
23.7 Hz, CF
aFb,rotamer2), -111.2
(1 F, br d, J = 246.0
Hz, CFa
F
b,rotamer1), -111.6
(1 F, br d, J = 246.0
Hz, CFa
F
b,rotamer2). ¹³C
NMR (75 MHz, CDCl3):
δ = 29.7
and 30.7 (t, J = 23.1
Hz), 40.2 (t, J = 5.2
Hz), 42.3 (d, J = 3.5
Hz), 46.3 (t, J = 3.5
Hz), 47.9 (d, J = 2.3
Hz), 67.5 (t, J = 26.5
Hz), 67.7 (t, J = 27.1
Hz), 116.3 (q, J = 287.7 Hz),
119.9 and 120.1 (t, J = 246.3
Hz), 156.7 (q, J = 36.5 Hz).
IR (ATR): ν = 3444, 1683, 1464,
1185, 1111, 967
cm-¹. MS
(ES+): m/z (%) = 251
(100) [M + NH4
+].
Anal. Calcd: C, 36.06; H, 3.46; N, 6.01. Found: C, 35.79; H, 3.09; N,
5.88.
<A NAME="RG09409ST-16">16</A>
4,4-Difluoro-3,3-dihydroxy-1-(trifluoroacetyl)piper-idine (14)
In a 10 mL flask, 4,4-difluoro-3-hydroxy-1-(trifluoro-acetyl)piperidine
(11, 0.10 g 0.43 mmol) was dissolved in anhyd
CH2Cl2 (5 mL). After adding Dess-Martin periodinane
(0.36 g, 0.86 mmol, 2.0 equiv), the solution was stirred for 15
h at r.t. The mixture was diluted with Et2O (30 mL),
and the organic phase was washed three times with a sat. aq NaHCO3 solution
(20 mL). The organic phase was dried over MgSO4, and
after filtration the solvent was evaporated in vacuo. The concentrate
was dissolved in Et2O (5 mL) and cooled to -40 ˚C
to crystallize residues of the Dess-Martin periodinane
reagent. After filtration of the solids, the filtrate was evaporated
in vacuo to yield 0.06 g of piperidine 14 (0.26
mmol, 60%). Ratio of rotamers = 2:1; colorless
oil. ¹H NMR (300 MHz, CDCl3): δmajor = 2.11-2.31 (2
H, m, NCH2CH
2),
3.71 (2 H, t, J = 6.1
Hz, NCH
2CH2), 3.83 [2
H, s, NCH
2C(OH)2],
5.52 (2 H, br s, 2 × OH);
δminor = 2.11-2.31
(2 H, m, NCH2CH
2),
3.67 [2 H, s, NCH
2C(OH)2],
3.78 (2 H, t, J = 6.1
Hz, NCH
2CH2), 5.52
(2 H, br s, 2 × OH). ¹9F
NMR (282 MHz, CDCl3): δ = -67.2
and -68.9 (3 F, s, CF3), -119.6 (2
F, t, J = 13.2
Hz, CF2,rotamer1), -119.7 (2 F, t, J = 13.2 Hz,
CF2,rotamer2). ¹³C
NMR (75 MHz, CDCl3): δmajor = 31.6
and 30.2 (t, J = 23.1
Hz), 40.2 (t, J = 4.6
Hz), 42.6 (m), 49.9 and 51.6, 90.8 and 91.5 (t, J = 24.2
Hz), 116.3 and 116.3 (q, J = 287.3
Hz), 118.7 and 119.0 (t, J = 250.9
Hz), 156.6 and 156.8 (q, J = 36.5
Hz). IR (ATR,): ν = 3410, 1685,
1461, 1187, 1112, 964 cm-¹. MS (ES+): m/z (%) = 267
(100)[M + NH4
+].
Anal. Calcd: C, 33.75; H, 3.24; N, 5.62. Found: C, 33.41; H, 3.49;
N, 5.43.
<A NAME="RG09409ST-17">17</A>
Bégué J.-P.
Bonnet-Delpon D.
Tetrahedron
1991,
47:
3207